OmniAb (OABI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 17, 2026, at 8:00 AM PT in Emeryville, CA.
Proxy materials and 2025 Annual Report are available online for review and voting.
Shareholders are encouraged to vote electronically or request paper materials by June 6, 2026.
Voting matters and shareholder proposals
Election of two directors: Matthew W. Foehr and Jennifer Cochran, Ph.D.
Ratification of Ernst & Young LLP as the independent registered public accounting firm.
Board recommends voting FOR all nominees and FOR the auditor ratification.
Board of directors and corporate governance
Board has nominated two individuals for election to the board.
Partial view of Summaries dataset, powered by Quartr API
Latest events from OmniAb
- Q1 2025 revenue rose 10.5% with new tech launches, narrowed loss, and guidance affirmed.OABI
Q1 20258 Jul 2026 - Innovative antibody discovery platform drives partner growth, clinical pipeline, and long-term royalties.OABI
Jefferies Global Healthcare Conference8 Jul 2026 - Q2 revenue rose to $7.6M, net loss narrowed, and new partnerships support future growth.OABI
Q2 20248 Jul 2026 - Q1 2026 revenue soared 247% to $14.4M, net loss narrowed, and guidance was raised.OABI
Q1 20268 May 2026 - Annual meeting to elect directors and ratify auditor, with strong governance and ESG focus.OABI
Proxy filing29 Apr 2026 - Over 400 active programs and new technology launches drive growth and future cash flow.OABI
Corporate presentation24 Mar 2026 - 107 partners, 407 programs, new platforms, and 2026 revenue growth expected.OABI
Q4 20254 Mar 2026 - Q3 revenue fell to $4.2M, but partner and program growth and $59.4M cash support future progress.OABI
Q3 202414 Jan 2026 - Double-digit partner and program growth, Q4 revenue up, 2025 revenue seen at $20–$25M.OABI
Q4 202424 Dec 2025